12:00 AM
 | 
Apr 04, 2011
 |  BC Week In Review  |  Company News  |  Deals

Newron, Merck KGaA deal

Merck KGaA's Merck Serono S.A. unit granted Newron an exclusive, worldwide license to develop Merck's CNS candidates pruvanserin and sarizotan. Newron will conduct preclinical testing and proof-of-concept (POC) studies in undisclosed indications, after which Merck has options to reacquire each compound. If...

Read the full 198 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >